For the treatment of gram-positive bacteria and mycoplasma infections. Long-term low-dose addition in livestock and poultry feeds can improve feed rewards, promote animal growth, and increase weight gain, thereby shortening the feeding cycle. Among them, the feed remuneration of chickens can be increased by 4.5 to 12.5%, and the weight gain rate can be increased by 4.5 to 15%; the feed remuneration of pigs can be increased by 11 to 25%, and the weight gain rate can be increased by 11 to 15%. Adding high doses to livestock and poultry feeds can prevent and treat swine dysentery, colitis, ileitis, necrotizing enteritis, maintain body weight in the event of atrophic rhinitis, and reduce diarrhea and edema caused by Escherichia coli in newborn and weaned piglets It can control the incidence of swine asthma and chronic respiratory disease in chickens caused by mycoplasma infection, reduce the stress response of livestock and poultry, and prevent and treat the secondary infection of sensitive bacteria in livestock and poultry after outbreaks of viral diseases.
Ningxia Taiyixin Biotechnology Co., Ltd. was established in 2010 and is located in Helan County Industrial Park (Nuanquan Area), Yinchuan City, Ningxia, with a registered capital of 768 million yuan, a planned land area of 3,300 mu, and a total investment of nearly 6 billion yuan. More than 1900 people. It is mainly committed to the research and development, production and sales of biomedicine, bio-veterinary drugs and bio-pesticides, and will strive to become a large-scale pharmaceutical enterprise with sustainable development of "safety, technological innovation, environment-friendly, quality and efficiency". The company has successively obtained the "National High-tech Enterprise" certificate, and has been included in the "National Industrial Internet Integration Application Pilot Demonstration Enterprise", "China's Foreign Trade Export Leading Index Sample Enterprise", "Ningxia Hui Autonomous Region Industrial Leading Enterprise" and "The District's Industrial Steady Growth" It ranks among the “Enterprise with Outstanding Contribution to Work” and is the “Biomedical Innovation Center” of the autonomous region. During the new crown epidemic in 2020, it was rated as "Key Enterprise for Epidemic Prevention and Control" by the Ministry of Industry and Information Technology of the People's Republic of China, and was rated as "Key Manufacturer of Epidemic Prevention Products" by the Department of Industry and Information Technology of the Autonomous Region. At present, the products have been sold to more than 120 countries and regions.